<DOC>
	<DOCNO>NCT01455701</DOCNO>
	<brief_summary>This multi-center , open label single arm study investigate pharmacokinetics safety tocilizumab ( TCZ ) ( RoActemra/Actemra ) participants less 2 year old active systemic juvenile idiopathic arthritis ( sJIA ) . Participants receive tocilizumab infusion every 2 week . The anticipated time study treatment 12 week ( Main evaluation period ) . Participants option continue TCZ treatment participant reach 2 year age one year baseline , whichever longer . An optional extension period follow main evaluation period .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetic Safety Tocilizumab ( RoActemra/Actemra ) Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Fulfills international league association rheumatology ( ILAR classification ) criterion sJIA Duration sJIA symptom last least 1 month subsequent diagnosis sJIA Presence active disease determine presence : 1 . Greater equal ( &gt; /= ) 2 active joint screen baseline , least 14 consecutive day temperature recording , may include presence absence fever ( &gt; /=38 degree celsius ) time screen baseline ; 2 . &gt; /=2 active joint screen baseline , fever &gt; /=38 degree celsius least 5 consecutive day time screen baseline ; circumstance participant need complete full 14 day temperature diary entry meet inclusion criterion Not currently receive corticosteroid ( CS ) take oral CS like prednisone equivalent , dose less equal ( &lt; /= ) 1 milligram per kilogram per day ( mg/kg/day ) dose remain stable least 2 week prior baseline Not currently receive methotrexate ( MTX ) take MTX ( together either folic acid folinic acid accord local standardofcare ) , dose remain stable discontinue least 4 week prior baseline Not currently receive nonsteroidal antiinflammatory drug ( NSAIDs ) take NSAID , dose remain stable discontinue least 2 week prior baseline If participant receive previous treatment follow biologic agent , must discontinue accord follow timeline prior baseline visit permit study : 1 . Etanercept must discontinue within &gt; /= 2 week prior baseline 2 . Anakinra must discontinue within &gt; /= 4 day prior baseline 3 . Abatacept must discontinue within &gt; /= 12 week prior baseline 4 . Infliximab adalimumab must discontinue within &gt; /= 8 week prior baseline 5 . Canakinumab must discontinue within &gt; /= 20 week prior baseline 6 . Rilonacept must discontinue within &gt; /= 6 week prior baseline 7 . Golimumab must discontinue within &gt; /= 10 week prior baseline 8 . Certrolizumab pegol must discontinue within &gt; /= 10 week prior baseline History inadequate clinical response ( opinion treat physician ) NSAIDs CS General Any autoimmune , rheumatic disease overlap syndrome sJIA Not fully recover recent surgery less six week since surgery , time screen visit ; plan surgery study ( except myringotomy surgery , permit ) General Safety Any significant concurrent medical surgical condition would jeopardize participant safety ability complete trial History significant allergic infusion reaction prior biologic therapy excipients list TCZ product label document Inborn condition characterize compromise immune system Known human immunodeficiency virus ( HIV ) infection acquire form immune compromise Evidence serious uncontrolled concomitant disease include limit nervous system , renal , hepatic endocrine system Asthma participant require use oral parenteral corticosteroid &gt; /=2 week within 6 month prior baseline visit Any active acute , subacute , chronic recurrent bacterial , viral systemic fungal infection History atypical tuberculosis ( TB ) Active TB require treatment point prior screen visit Positive TB test result screen , unless treat antituberculosis therapy least 4 week prior receive study medication chest radiograph negative active tuberculosis within 6 month screen visit consistent local practice Any major episode infection require hospitalization treatment screen treatment intravenous ( IV ) antibiotic complete within 4 week screen visit oral antibiotic complete within 2 week screen visit History reactivation new onset systemic infection herpes zoster Epstein Barr virus within 2 month screen visit History hepatitis B hepatitis C infection Chronic hepatitis viral autoimmune Significant cardiac pulmonary disease History concurrent serious gastrointestinal disorder ulcer inflammatory bowel disease , ulcerative colitis symptomatic low gastrointestinal condition , include ulcer perforation History current cancer lymphoma History macrophage activation syndrome ( MAS ) within 3 month prior screen visit Uncontrolled diabetes mellitus elevate hemoglobin ( Hgb ) A1c define agespecific standard Excluded Previous Concomitant Therapy : Participation another interventional clinical trial within past thirty day five serum halflives investigative medication , whichever longer Previous treatment TCZ Administration intravenous immunoglobulin within 4 week prior baseline visit Previous treatment cell deplete therapy , include investigational agent Prior stem cell transplant time Live attenuate vaccine within 4 week prior baseline visit , intend receive study medication 8 week follow last dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>